Innotox us the world’s first liquid injectable form of botulinum Toxin type A approved by KFDA in South Korea, 2013. Allergan, the Botox manufacturer, made an exclusive license agreement to market Innotox worldwide, excluding Korea and Japan.
Warning: Last items in stock!
Innotox us the world’s first liquid injectable form of BoNT-A approved by KFDA in South Korea, 2013. Innotox is provided as a ready to use sterile liquid with 4U/0.1ml concentration. Therefore, no risk of contamination or inaccurate dosing due to human errors during reconstitution exists, which ultimately enhances the treatment safety and efficacy. Furthermore, its storage and reuse are more convenient, and Innotox has a long stability with an expiration of 36 months under 2 to 8 degree storage conditions.
1 Vial/50 U
Innotox is predicted by the same Hall strain of C.botulinum as Neuronox and Botox. The molecular weight of Innotox analyzed using size exclusion SE-HPLC is approximately 900 kDa. Which is highly comparable to those of Neuronox and Botox.
Another key characteristic of Innotox is that it excludes the use of substances of animal origin in the manufacturing process to eliminate the risks associated with animal-based proteins. Moreover, it excludes human serum albumin as an excipient of the final product to avoid any risk associated with diseases of human blood origin. Instead it contains methionine and polysorbate as a stabilizer.
The safety and efficacy of Innotox and Botox were compared at a 1:1 dose ratio for treating glabellar lines in a double-blinded, randomized, phase III multi center study with 168 subjects. The patients, aged 20 to 65 years with moderate-to-severe glabellar lines, were randomly treated with 20U of Innotox or Botox and subsequently assessed by blinded investigators. The improvement rate at both maximum frown and rest was not significantly different between the Innotox and Botox groups. No severe adverse drug reactions were observed.
With these advantages, Allergan, the Botox manufacturer, made an exclusive license agreement to market Innotox worldwide, excluding Korea and Japan. It is available in vials of 25U and 50U.